- Home
- TEI vs ALLO Comparison
TEI vs ALLO Comparison
Compare TEI & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEI
- ALLO
- Stock Information
- Founded
- TEI 1993
- ALLO 2017
- Country
- TEI United States
- ALLO United States
- Employees
- TEI N/A
- ALLO N/A
- Industry
- TEI Finance Companies
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TEI Finance
- ALLO Health Care
- Exchange
- TEI Nasdaq
- ALLO Nasdaq
- Market Cap
- TEI 282.9M
- ALLO 252.9M
- IPO Year
- TEI N/A
- ALLO 2018
- Fundamental
- Price
- TEI $6.28
- ALLO $1.33
- Analyst Decision
- TEI
- ALLO Buy
- Analyst Count
- TEI 0
- ALLO 11
- Target Price
- TEI N/A
- ALLO $8.67
- AVG Volume (30 Days)
- TEI 142.4K
- ALLO 2.4M
- Earning Date
- TEI 01-01-0001
- ALLO 11-06-2025
- Dividend Yield
- TEI 10.51%
- ALLO N/A
- EPS Growth
- TEI N/A
- ALLO N/A
- EPS
- TEI N/A
- ALLO N/A
- Revenue
- TEI N/A
- ALLO N/A
- Revenue This Year
- TEI N/A
- ALLO N/A
- Revenue Next Year
- TEI N/A
- ALLO $100.00
- P/E Ratio
- TEI N/A
- ALLO N/A
- Revenue Growth
- TEI N/A
- ALLO N/A
- 52 Week Low
- TEI $4.35
- ALLO $0.86
- 52 Week High
- TEI $5.39
- ALLO $3.78
- Technical
- Relative Strength Index (RSI)
- TEI 44.27
- ALLO 59.50
- Support Level
- TEI $6.27
- ALLO $1.20
- Resistance Level
- TEI $6.50
- ALLO $1.35
- Average True Range (ATR)
- TEI 0.08
- ALLO 0.09
- MACD
- TEI -0.02
- ALLO 0.01
- Stochastic Oscillator
- TEI 5.98
- ALLO 95.16
About TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.